

# **UCLA**

## **UCLA Previously Published Works**

### **Title**

Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis.

### **Permalink**

<https://escholarship.org/uc/item/2bp544gm>

### **Journal**

PloS one, 6(10)

### **ISSN**

1932-6203

### **Authors**

Luo, Guanpingsheng  
Ibrahim, Ashraf S  
French, Samuel W  
et al.

### **Publication Date**

2011

### **DOI**

10.1371/journal.pone.0025909

Peer reviewed

# Active and Passive Immunization with rHyr1p-N Protects Mice against Hematogenously Disseminated Candidiasis

Guanpingsheng Luo<sup>1</sup>, Ashraf S. Ibrahim<sup>1,2</sup>, Samuel W. French<sup>2,3</sup>, John E. Edwards Jr.<sup>1,2</sup>, Yue Fu<sup>1,2\*</sup>

**1** Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America, **2** David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America, **3** Department of Pathology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America

## Abstract

We previously reported that *Candida albicans* cell surface protein Hyr1 encodes a phagocyte killing resistance factor and active vaccination with a recombinant N-terminus of Hyr1 protein (rHyr1p-N), significantly protects immunocompetent mice from disseminated candidiasis. Here we report the marked efficacy of rHyr1p-N vaccine on improving the survival and reducing the fungal burden of disseminated candidiasis in both immunocompetent and immunocompromised mice using the FDA-approved adjuvant, alum. Importantly, we also show that pooled rabbit anti-Hyr1p polyclonal antibodies raised against 8 different peptide regions of rHyr1p-N protected mice in a hematogenously disseminated candidiasis model, raising the possibility of developing a successful passive immunotherapy strategy to treat this disease. Our data suggest that the rabbit anti-Hyr1p antibodies directly neutralized the Hyr1p virulence function, rather than enhanced opsonophagocytosis for subsequent killing by neutrophil *in vitro*. Finally, the rHyr1p-N vaccine was protective against non-*albicans Candida spp.* These preclinical data demonstrate that rHyr1p-N is likely to be a novel target for developing both active and passive immunization strategies against *Candida* infections.

**Citation:** Luo G, Ibrahim AS, French SW, Edwards JE Jr, Fu Y (2011) Active and Passive Immunization with rHyr1p-N Protects Mice against Hematogenously Disseminated Candidiasis. PLoS ONE 6(10): e25909. doi:10.1371/journal.pone.0025909

**Editor:** Marta Feldmesser, Albert Einstein College of Medicine, United States of America

**Received:** June 27, 2011; **Accepted:** September 13, 2011; **Published:** October 10, 2011

**Copyright:** © 2011 Luo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by Public Health Service grants R01 AI19990 and AI063382 to JEE and R21 AI066010 and R03 AI083251 to YF. ASI is supported by Public Health Service grant R01 AI063503 and R21 AI082414. NovaDigm Therapeutics, Inc. partially provided financial support for these studies. ASI, JEE, and YF did have a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. The Public Health Service had no role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.

**Competing Interests:** The authors have read the journal's policy and have the following conflict: ASI, JEE, and YF own equity in NovaDigm Therapeutics, Inc., which is developing vaccine technologies. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

\* E-mail: yfu@labiomed.org

## Introduction

*Candida* species, the third most common cause of healthcare-associated bloodstream infections [1] causes approximately 60,000 cases of hematogenously disseminated candidiasis per year in the United States [2], resulting in billions of dollars of healthcare expenditures. Notwithstanding current antifungal therapy [3,4,5], mortality remains unacceptably high [6,7,8]. Because of the rising incidence of life-threatening candidiasis and high treatment failure rates, more effective prophylactic and therapeutic strategies are needed.

*HYR1* belongs to the *IFF* gene family of *C. albicans*, which includes 12 members [9]. It encodes a cell surface glycosylphosphatidylinositol (GPI)-anchored protein that is expressed during hyphal formation [10,11]. In our previous study, we showed that Hyr1p mediated *C. albicans* resistance to phagocyte killing *in vitro* and contributed higher fungal burden in organs rich in phagocytes (e.g. liver and spleen) [12]. Native *HYR1* is positively regulated by transcription factor Bcr1p [13]. We found that autonomous *HYR1* expression reversed the hyper-susceptibility to phagocyte-mediated killing of a *bcrl* null mutant of *C. albicans in vitro* [12]. Further, heterologous expression of *HYR1* in *C. glabrata* rendered the organism more resistant to phagocyte killing [12]. Our study also showed that a vaccine based on the recombinant N terminus of Hyr1p (rHyr1p-N) markedly improved survival of immunocom-


petent mice challenged intravenously with *C. albicans* when mixed with either Freund's or alum as an adjuvant [12].

The current studies were performed to further define the vaccine efficacy of rHyr1p-N vaccine in both immunocompetent and immunocompromised mice using the FDA-approved alum as an adjuvant. Further, the breadth of protection induced by rHyr1p-N was evaluated by its efficacy against non-*albicans Candida* species. Finally, we sought to study the potential use of passive immune therapy in disseminated candidiasis using anti-Hyr1p antibodies.

## Results

**The rHyr1p-N vaccine significantly improved survival and decreased fungal burden in immunocompetent mice challenged intravenously with *C. albicans***

To determine the most effective dose of the rHyr1p-N immunogen, an approximately 3-fold dose range was evaluated (1 to 33 µg per mouse). Female juvenile BALB/c mice were immunized with rHyr1p-N plus alum (2% Alhydrogel; Brenntag Biosector) or with alum alone. These mice were subsequently infected with a lethal inoculum of *C. albicans* ( $7 \times 10^5$  blastospores). Vaccinated mice had significant improvements in survival compared to adjuvant control mice (Figure 1A). All tested doses, except 1 µg, prolonged or improved survival compared to mice



**Figure 1. rHyr1p-N vaccine improved survival and decreased fungal burden in mice with *C. albicans* infection.** (A) Survival of vaccinated or control mice ( $n=15$  per group) infected intravenously with *C. albicans* 15563 strain, a clinical isolate ( $9 \times 10^5$  per dose), \*  $P < 0.001$  compared to alum alone by the log-rank test. (B) Kidney fungal burden of mice ( $n=10$  per arm) vaccinated with  $33 \mu\text{g}$  rHyr1p-N + alum or alum alone and harvested 3 days post infection with *C. albicans* 15663 ( $7 \times 10^5$  per dose). Data are presented as median  $\pm$  interquartile ranges. \*  $P < 0.001$  compared to results obtained from mice vaccinated with alum alone by the Mann-Whitney U test. doi:10.1371/journal.pone.0025909.g001

receiving adjuvant alone, and a dose response was found with 10 and  $33 \mu\text{g}$  having the greatest efficacy (Figure 1A). The experiment was terminated on day 28, with all remaining mice appearing healthy.

To determine the impact of vaccination on fungal burden, juvenile mice were vaccinated and infected as above. On day 3 post-infection (one day before the control mice were predicted to die based on the previous experiment), mice were euthanized and kidneys, being the primary target organ, were harvested to determine tissue fungal burden. Vaccination reduced the tissue fungal burden by approximately 16-fold compared to control mice ( $p < 0.001$ ) (Figure 1B).

Consistent with the survival and fungal burden data, histopathological examination of kidneys harvested from rHyr1p-N vaccinated mice demonstrated very few abscesses with minimal fungal residues mainly present in the blastospore formation (Figure 2B). However, numerous abscesses full of fungal cells showing mostly yeast forms with some hyphae and pseudohyphae were detected in kidneys taken from mice vaccinated with alum alone (Figure 2A). Semi-quantitative evaluation of the severity of infection showed a significant reduction of abscesses per field as well as reduced *Candida* cells per abscess in vaccinated mice compared to that in controls (Fig. 2C,  $P < 0.0001$ ).

## The rHyr1p-N effectively protected immunocompromised mice against candidiasis

It is known that a significant fraction of immunocompromised patients do respond to a variety of vaccines [14,15,16,17]. We sought to define the potential usage of the rHyr1p-N vaccine to protect neutropenic mice from disseminated candidiasis. Immunized mice were bled twelve days following the boost with  $30 \mu\text{g}$  of rHyr1p-N. Vaccination significantly increased the mouse immune response as determined by detection of increased anti-rHyr1p-N antibody titers ( $P = 1.08 \times 10^{-5}$ ) (Figure 3A). One day after the bleeding, mice were made neutropenic. Vaccination resulted in significant improvements in survival ( $P = 0.007$  versus control) (Figure 3B).

We also evaluated the kidney fungal burden on day 10 post infection. Concordant with our survival result, we found that mice vaccinated with  $30 \mu\text{g}$  of rHyr1p-N had 1.50 log fold decrease in fungal burden compared to kidneys harvested from control mice (Figure 3C,  $P = 0.002$ ).

## Passive immunization with anti-Hyr1p IgG prolonged the survival of mice infected with *C. albicans*


Since some patients might not respond to an active vaccine strategy, we evaluated the possibility of using passive immunotherapy targeting Hyr1p. We generated polyclonal antibodies by vaccinating rabbits with 8 hydrophilic, highly antigenic 14-mer peptides located within rHyr1p-N region (Table 1). Purified IgG targeting these 8 peptides were pooled and used to treat naïve mice infected with a lethal dose of *C. albicans*. Mice receiving anti-Hyr1p IgG at either 1 or 3 mg (but not when administered at 0.3 mg) were protected substantially from infection when compared to mice receiving non-specific, rabbit control IgG from commercial source (Figure 4A, 4B and 4C).

To determine if the generated anti-Hyr1p antibodies enhanced phagocyte function by increasing opsonophagocytosis or by neutralizing Hyr1 killing resistance, we isolated and prepared  $F(ab')_2$  fragments from pooled IgG raised against the 8 peptides of Hyr1p (conjugated to keyhole limpet hemocyanin or KLH) or from non-specific, rabbit control IgG. These fragments were used in HL-60 derived neutrophil killing assay against *C. albicans* conditionally overexpressing or suppressing Hyr1p rather than wild-type *C. albicans* to demonstrate specificity of these fragments to Hyr1p and not to other members of IFF family [9]. Consistent with our previous mouse IgG data [12], we found that  $F(ab')_2$  fragments prepared from anti-Hyr1p antibodies but not those prepared from control antibodies were able to restore HL-60 derived neutrophil killing of the *HYR1* conditional expressing strain to levels equivalent to that of the suppressing strain (Figure 4D).

To verify that the protection elicited by antibodies was indeed due to anti-Hyr1p antibodies and not due to non-specific protection caused by antibodies reacting to unrelated immunogen such as peptide carrier protein KLH, the purified IgG targeting the 8 hydrophilic rHyr1p-N peptides was absorbed with *C. albicans* hyphae prior to testing for their protective activity against hematogenously disseminated candidiasis. The absorbed IgG did not stain *C. albicans* hyphae (Figure 5A), indicating the anti-Hyr1p IgG were successfully eliminated. Furthermore, similar to non-specific, rabbit control IgG, the absorbed IgG did not protect mice from *C. albicans* infection, whereas the purified, non-absorbed IgG did (Figure 5B,  $P = 0.002$ ).

## The rHyr1p-N vaccine substantially reduced tissue fungal burden in BALB/c mice challenged with several non-*albicans* species of *Candida*


A vaccine that elicits protection against *C. albicans* and other non-*albicans* species is highly desirable because a significant



**Figure 2. Representative histopathological sections from kidneys were shown.** (A) Control mice infected with *C. albicans* had multiple abscesses showing mostly yeast forms with some hyphae and pseudohyphae throughout the kidneys. (B) rHyr1p-N vaccinated mice (33 μg) infected with *C. albicans* had less abscesses with far less fungi visible. (C) Semiquantitative evaluation of the severity of infection indicated significant abscess and *Candida* cells reduction in vaccinated mice compared to control mice. Sections were stained by PAS. Thirty random fields were examined by a blinded assessor (GL) to assess the number of lesions per field. Number of organisms per lesion was evaluated in 120 lesions in the control unvaccinated mice. The average number of organisms per lesion was determined by dividing the total number of fungal cells by the number of lesions counted. \*  $P < 0.0001$  by Wilcoxon rank sum test. doi:10.1371/journal.pone.0025909.g002

number of *Candida* infections are caused by non-*albicans* species. For example, *C. glabrata* represents the second most common cause of candidiasis and *C. krusei* is resistant to azole therapy. Using blast

searches we were able to detect Hyr1p like molecules in several *Candida* species with amino acid similarity ranging between 47–72% in certain areas. Thus, we vaccinated mice with rHyr1p-N



**Figure 3. rHyr1p-N vaccine prolonged survival and decreased fungal burden in neutropenic mice infected with *C. albicans*.** Balb/c mice ( $n = 20$  per arm) were vaccinated with rHyr1p-N mixed with alum or alum alone (control), treated with cyclophosphamide, and then infected with *C. albicans* 15563 at  $1 \times 10^5$  blastospores. Two days before cyclophosphamide treatment, half of the mice were bled and individually marked for antibody titer using ELISA (A) (rHyr1p-N vaccinated versus control, \* $P = 1.08E-05$  by Wilcoxon rank-sum test) and survival (B) (rHyr1p-N vaccinated versus control, \* $P = 0.007$  by log rank test). The other half mice were used for fungal burden (C) \*  $P = 0.002$  by Wilcoxon rank-sum test. doi:10.1371/journal.pone.0025909.g003

**Table 1.** Hyr1 peptides used in this study.

Peptide Number	Sequence	MW (kDa)	pI	Purity (%)	Source
1	CGPSAPESLNTNP	1.5	3.44	86.1	This study
2	CGNRDHFREYYPDT	1.9	5.69	99.4	This study
3	CGYDVKLFRIIVNSRG	1.7	9.16	95.7	This study
4	CKIKGTGCVTADEDT	1.5	4.70	86.4	This study
5	CLKNAVITYDGPVPNN	1.6	6.25	94.1	This study
6	NSKSSTSFNFIDIGC	1.6	6.25	91.4	This study
7	CEPTHNFYGLKDSKSS	1.8	7.19	85.8	This study
8	TSRIDRGIIQGFHGC	1.6	8.27	91.8	This study

Additional cysteine residues on the N- or C-termini were used to conjugate the 14-mer peptide to KLH.

doi:10.1371/journal.pone.0025909.t001


plus alum as above, then challenged with *C. albicans*, *C. glabrata*, *C. krusei*, *C. parapsilosis*, or *C. tropicalis*. Three days post infection mice were sacrificed and the kidneys harvested for determination of tissue fungal burden through colony counts. Mice vaccinated with rHyr1p-N had 0.65–1.69 log decrease in kidney fungal burden

compared to mice vaccinated with alum alone (Figure 6,  $P < 0.001$ ).


## Discussion

*C. albicans* vaccine development has focused on using cell surface components [18,19], peptides derived from cell wall proteins as immunogens [20], or on antibodies targeting cell surface components [21,22]. Our group has been working for decades towards developing immunotherapeutic approaches to prevent or ameliorate disseminated, healthcare-associated fungal infections. These efforts have resulted in the initiation of a Phase I clinical trial of our anti-*Candida* vaccine that targets the Als3p, a known adhesin/invasion [23].

In our efforts to develop additional protective antigens against *Candida*, we have identified properties of the recombinant N-terminus of Hyr1p (rHyr1p-N) [12] that make it highly desirable for further development as both active and passive immunotherapy target. In our previous study, we demonstrated by using indirect immunofluorescence that Hyr1p is expressed on the cell surface of *C. albicans* hyphae [12]. These findings were further confirmed by our comparative indirect immunofluorescence of *C. albicans* using purified IgG raised against 8 hydrophilic peptides of rHyr1p-N pre- and post-absorption with *C. albicans* hyphae and



**Figure 4. Dose dependent passive immunization with anti-Hyr1p IgG protected against murine hematogenously disseminated candidiasis.** Mice were given 0.3 mg (A), 1 mg (B) and 3 mg (C) of anti-Hyr1p IgG by intraperitoneal injection 2 hr before infecting with  $6.2 \times 10^5$  blastospores of *Candida albicans* 15563 via the tail vein. Survival of mice ( $n = 10$  per group) was monitored twice daily. \*  $P = .001$  by log-rank test vs. mice receiving non-specific, rabbit control IgG. (D) Effect of vaccinated or control F(ab')<sub>2</sub> on blocking HL-60 derived neutrophil killing of *C. albicans*. *C. albicans* overexpressing or suppressing Hyr1p were used in the assay to demonstrate specificity of the F(ab')<sub>2</sub> fragments to Hyr1p. Control denotes assay performed either in the absence of F(ab')<sub>2</sub> or in the presence of F(ab')<sub>2</sub> from non-specific, rabbit control IgG. Data are displayed as median  $\pm$  interquartile range. \*  $P = .001$  by Mann-Whitney test. doi:10.1371/journal.pone.0025909.g004



**Figure 5. Protection against hematogenously disseminated candidiasis using purified pooled IgG was specific to Hyr1p.** A) Indirect immunofluorescence with rabbit anti-Hyr1p IgG demonstrated surface expression of Hyr1p on *C. albicans* hyphae and the successful absorption of anti-Hyr1p antibodies; B) Survival of mice treated with 1 mg of: 1) pooled anti-Hyr1p IgG (n=20); 2) pooled anti-Hyr1p IgG absorbed with *C. albicans* hyphae (n=10); or 3) rabbit control IgG (n=20) 2 hr before infecting with  $8.7 \times 10^5$  blastospores of *C. albicans* 15563 via the tail vein. The antibody dose was repeated 3 days after infection. \*  $P=0.002$  for pooled anti-Hyr1p IgG vs. absorbed IgG, \*  $P=0.03$  for pooled anti-Hyr1p IgG vs. control IgG, \*\*  $P=0.28$  for control IgG vs. absorbed IgG by Log Rank test.  
doi:10.1371/journal.pone.0025909.g005

control IgG (Figure 5A). We hypothesized that immunotherapies targeting the cell wall Hyr1p would have the dual benefit of the immune system recognizing the fungus and enhancing phagocyte killing of *Candida*. In this study, our data on rHyr1p-N has shown efficacy in animal models at doses 10–30 times less than those used for rAls3p-N (i.e. ~50% survival for 10–33  $\mu$ g dose for rHyr1p-N vs. 300  $\mu$ g dose of rAls3p-N) [12,19,24]. Additionally, the mechanism of action appears to be considerably different from that of rAls3p-N. Rabbit polyclonal IgG raised against 8 different 14-mer peptides from regions of rHyr1p-N substantially protects mice from experimental disseminated candidiasis, whereas, our previous studies indicated that the mechanism of action of the rAls3p-N vaccine is dominantly dependent on T cells and anti-rAls3p-N antibodies are not the central mechanism of protection [19,24]. Furthermore, the rHyr1p-N maintained its efficacy in the neutropenic mouse model. These findings suggest that Hyr1p is a promising target for both active and passive immunization.


Tissue fungal burden and histopathological examination of kidneys harvested from mice vaccinated with rHyr1p-N or alum alone further confirmed the efficacy of the rHyr1p-N vaccine. However, it appears that the histopathology difference between the control (Figure 2A) and rHyr1p-N vaccinated mice (Figure 2B) was more prominent than that of tissue fungal burden of the same

organs. In this regard, it has been previously reported that colony counting can underestimate the tissue fungal burden in the presence of hyphae and pseudohyphae [25,26], likely because tissue homogenization kills fungal filaments. We found that control mice had significantly more filamentous fungi in kidneys than vaccinated mice which had less abscesses mainly consisting of yeast form fungal elements. Therefore, tissue homogenization likely artificially lowers the colony counts for kidneys harvested from control mice but not from rHyr1p-N-vaccinated mice, making the difference less prominent.

Our results also show a dose response of anti-Hyr1p IgG in protecting mice from disseminated candidiasis. We confirmed that the protection elicited by anti-Hyr1p IgG was specific to Hyr1p since absorbed IgG with *C. albicans* hyphae lost its ability to protect mice against hematogenously disseminated candidiasis (Figure 5B). These results suggest that the mechanism of protection rendered by rHyr1p-N appears to be attributed, at least in part, to protective antibody response. Further studies to elucidate the role of T-cells vs. B-cells in the mechanism of rHyr1p-N protection against disseminated candidiasis are currently under active investigation.

In this study, we show that pooled IgG raised against 8 Hyr1 peptides directly neutralized the function of Hyr1p in resisting phagocyte killing rather than enhanced opsonophagocytosis. This





**Figure 6. rHyr1p-N vaccine reduces tissue fungal burden in BALB/c mice infected with non-*albicans* species of *Candida*.** BALB/c mice (n = 10 per group) were vaccinated with alum or alum plus rHyr1p-N (30 µg) and boosted three weeks later. Two weeks after the boost, mice were challenged via the tail vein with *C. glabrata* ( $3.2 \times 10^7$ ), *C. krusei* ( $3.4 \times 10^7$ ), *C. parapsilosis* ( $9.6 \times 10^6$ ), or *C. tropicalis* ( $3.2 \times 10^6$ ). Kidney fungal burden was determined on day 3 post infection. The y axis reflects the lower limit of detection of the assay. \*  $P < 0.001$  versus adjuvant control by the Mann-Whitney U test. doi:10.1371/journal.pone.0025909.g006

is evident by the ability of F(ab')<sub>2</sub> fragments (prepared from anti-rHyr1p-N antibodies) to restore phagocyte killing of *C. albicans* overexpressing Hyr1p to levels equivalent to that of the suppressing strain (Figure 4D). However, the rHyr1p-N vaccine maintained its efficacy in neutropenic mice. This can be explained by the fact that cyclophosphamide induces leukopenia in mice with minimal effect on tissue phagocytes. Further experimentation is necessary to determine specific peptide(s) by which antibodies are generated to protect the host against disseminated candidiasis.

In summary, the rHyr1p-N vaccine is a promising candidate for further development. The vaccine is efficacious in both immunocompetent and immunocompromised mice, when mixed with alum as an adjuvant, against multiple clinical isolated strains of *C. albicans* [12], and against several non-*albicans* *Candida* species.

## Materials and Methods

### Candida strains and growth conditions

*C. albicans* 15663, *C. glabrata* 31028, *C. parapsilosis* 22019 and *C. tropicalis* 4243 are clinical bloodstream isolates collected from Harbor-UCLA Medical Center. *C. krusei* 91-1159 was generously provided by Michael Rinaldi, San Antonio, TX). *C. albicans* strains CAAH-31 and THE31 were engineered as described in our previous study and doxycycline was used to regulate the *HYR1* expression [12]. All tested strains were routinely grown in YPD (2% Bacto Peptone, 1% yeast extract, 2% dextrose). Cell densities were determined by counting in a hemacytometer.

### rHyr1p-N production

6×His tagged rHyr1p-N was produced in *E. coli* and purified by Ni-agarose affinity column as previously described [12]. Endotoxin was removed from rHyr1p-N using ProteoSpin Endotoxin Removal kit (Norgen Biotech Corporation, Ontario, Canada), and the endotoxin level was determined with Limulus Amebocyte Lysate endochrome (Charles River Laboratories, Wilmington,

MA) per manufacturer's instruction. Using this procedure, endotoxin was reduced to <0.1 EU per dose of the vaccine.

### Synthetic peptides and rabbit anti-Hyr1p polyclonal antibodies

Eight peptides derived from rHyr1p-N (Table 1) were commercially synthesized and used to generate anti-Hyr1p antibodies. Peptides were >85% pure as determined by HPLC and mass spectrometry (GenScript, Piscataway, NJ). They were conjugated to keyhole limpet hemocyanin (KLH) through additional cysteine from either N- or C- terminus before raising rabbit antiserum individually using a standard immunization protocol (GenScript, Piscataway, NJ). Total IgG from pooled serum was affinity purified using Pierce Protein A plus Agarose (Thermo Scientific, Rockford, IL) per the manufacturer's instruction prior to administering in passive immunization studies.

### Immunofluorescence detection of Hyr1p cellular localization

Indirect immunofluorescence was performed using pooled rabbit anti-Hyr1p IgG raised against 8 peptides of rHyr1p-N as previously described [12]. In brief, *C. albicans* blastospores ( $1 \times 10^7$ ) were pre-germinated in RPMI 1640 for 90 min at 37°C and transferred into a 4-well chamber slide (Nalge Nunc International). After incubation at 4°C for 30 min, the cells were blocked with 300 µl of 1.5% mouse serum, then stained with 1:500 dilution of either 1) pooled anti-Hyr1p IgG, 2) pooled anti-Hyr1p IgG absorbed with *C. albicans* hyphae (by incubating the pooled IgG repeatedly for 4 times with  $1 \times 10^7$  *C. albicans* hyphae for 30 min each time on ice), or 3) rabbit control IgG. The cells were counterstained with fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG at 1:100 dilution prior to imaging with Zeiss Axioskop fluorescence microscopy.

### Immunization protocol and animal studies

All active vaccinations were conducted as previously described [12]. In brief, juvenile (10–12 week) Balb/C mice were vaccinated subcutaneously with 30 µg of rHyr1p-N mixed with alum (2% Alhydrogel; Brenntag Biosector, Frederikssund, Denmark) as an adjuvant in phosphate buffered saline (PBS) on day 0, boosted with the same dose on day 21, then infected via the tail vein on day 35 [27]. Control mice were vaccinated with alum alone.

To test the efficacy of the vaccine in immunocompromised mice, mice were vaccinated as above prior to inducing neutropenia by intraperitoneal injection of 200 mg/kg of cyclophosphamide on day -2 followed by another dose of 100 mg/kg on day +7 relative to infection. This regimen results in approximately 10 days of leucopenia with reduction in neutrophil, lymphocyte and monocyte counts, as described previously [28,29,30]. For both immunocompetent and neutropenic mice differences in survival between vaccinated and adjuvant vaccinated mice were compared by the Log Rank test.

For passive immunization, immune IgG was administered intraperitoneally to naïve mice 2 hr before infecting intravenously with *C. albicans*. Control mice were given non-specific, rabbit IgG (Innovative Research, USA). IgG doses were repeated 3 days after infection, and survival of mice was monitored twice daily.

Quantitative culturing of kidneys from vaccinated or control mice infected with different species of *Candida* was performed as previously described [31]. In brief, mice were infected through tail veins. Kidneys were harvested 3 days post infection, homogenized, serially diluted in 0.85% saline, and quantitatively cultured on YPD that contained 50 µg/ml chloramphenicol. Colonies were

counted after incubation of the plates at 37°C for 24 to 48 hr, and results were expressed as log CFU per gram of infected organ.

Concomitant with the fungal burden experiment, kidneys were removed aseptically from two mice per group for histopathological examination. Kidneys were immersed in zinc formalin fixative until examination. Fixed organs were dehydrated in graded alcohol solutions, embedded in paraffin, and cut into 6- $\mu$ m-thick sections. Mounted sections were stained with Gomori methenamine silver and examined by light microscopy [32].

### Enzyme-linked immunosorbent assay (ELISA)

To test if the rHyr1p-N vaccine induced an immune response, antibody titers of serum samples collected from vaccinated and control mice were determined by ELISA in 96-well plates as previously described [27]. Wells were coated at 100  $\mu$ l per well with rHyr1p-N at 5  $\mu$ g/ml in PBS. Mouse sera were incubated for 1 hr at room temperature following a blocking step with Tris-buffered saline (TBS; 0.01 M Tris HCl [pH 7.4], 0.15 M NaCl) containing 3% bovine serum albumin. The wells were washed three times with TBS containing 0.05% Tween 20, followed by another three washes with TBS. Goat anti-mouse secondary antibody conjugated with horseradish peroxidase (Sigma) was added at a final dilution of 1:5000, and the plate was further incubated for 1 hr at room temperature. Wells were washed with TBS and incubated with substrate containing 0.1 M citrate buffer (pH 5.0), 50 mg of *o*-phenylenediamine (Sigma), and 10  $\mu$ l of 30% H<sub>2</sub>O<sub>2</sub>. The color was allowed to develop for 30 min, after which the reaction was terminated by addition of 10% H<sub>2</sub>SO<sub>4</sub> and the optical density (OD) at 490 nm was determined in a microtiter plate reader. Negative control wells received only diluent, and background absorbance was subtracted from the test wells to obtain final OD readings. The ELISA titer was taken as the reciprocal of the last serum dilution that gave a positive OD reading (i.e., more than the mean OD of negative control samples plus 2 standard deviations).

### F(ab')<sub>2</sub> blocking assay

To study the mechanism of protection mediated by anti-Hyr1p antibodies in phagocyte-mediated killing of *C. albicans*, HL-60 cells that have been differentiated to neutrophil-like phenotype were used [12]. Killing assay was conducted in the presence of anti-Hyr1p IgG or F(ab')<sub>2</sub> fragments as described before [12]. In brief, HL-60 cells were induced with 2.5  $\mu$ M of retinoic acid and 1.3% DMSO for 3 days at 37°C with 5% CO<sub>2</sub>. Immune anti-Hyr1

peptides (Table 1) sera were pooled and total IgG was isolated using protein A agarose (Thermo Scientific). Serum collected from the same rabbits prior to immunization with the peptides served as control serum. The F(ab')<sub>2</sub> fragments from immune or control IgG were purified with Pierce F(ab')<sub>2</sub> Preparation Kit according to the manufacturer's instruction. SDS-PAGE analysis indicated >95% of Fc fragment was digested by this kit (data not shown). Next, *C. albicans* cells overexpressing or suppressing Hyr1p [12] were incubated with 50  $\mu$ g/ml of vaccinated or control F(ab')<sub>2</sub> fragments on ice for 45 min. *C. albicans* cocultured with the F(ab')<sub>2</sub> fragments were incubated with HL-60 derived neutrophils for 1 hr at 37°C with 5% CO<sub>2</sub> prior to sonication and quantitative culturing on YPD plates. % killing was calculated by dividing the number of CFU after coculturing with HL-60 derived neutrophils by the number of CFU from *C. albicans* incubated with media without HL-60 derived neutrophils.

### Statistical analysis

The nonparametric log rank test was used to determine differences in the survival times of the mice. Neutrophil killing assay, titers of antibody, and tissue fungal burden were compared by the Mann-Whitney U test or Wilcoxon rank sum test for unpaired comparisons. Correlations were calculated with the Spearman rank sum test. *P* values of <0.05 were considered significant.

All procedures involving mice were approved by the Los Angeles Biomedical Research Institute animal use and care committee for the project 11672-05 specifically to this vaccine study, following the National Institutes of Health guidelines for animal housing and care. The institute has a US Public Health Service approved animal welfare assurance number A3330-01.

### Acknowledgments

Research described in this manuscript was conducted at the research facilities of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The authors gratefully acknowledge the helpful discussions with John P. Hennessey, Jr. and Timothy Cooke.

### Author Contributions

Conceived and designed the experiments: GL ASI JEE YF. Performed the experiments: GL ASI SWF YF. Analyzed the data: GL ASI SWF JEE YF. Wrote the paper: GL ASI JEE YF.

### References

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis* 39: 309–317.
2. Spellberg B, Filler SG, Edwards JE, Jr. (2006) Current Treatment Strategies for Disseminated Candidiasis. *Clin Infect Dis* 42: 244–251.
3. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, et al. (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis* 37: 634–643.
4. Neely MN, Ghannoum MA (2000) The exciting future of antifungal therapy. *Eur J Clin Microbiol Infect Dis* 19: 897–914.
5. Groll AH, Piscitelli SC, Walsh TJ (1998) Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. *Adv Pharmacol* 44: 343–500.
6. Nucci M, Pulcheri W, Spector N, Bueno AP, Bacha PC, et al. (1995) Fungal infections in neutropenic patients. A 8-year prospective study. *Rev Inst Med Trop Sao Paulo* 37: 397–406.
7. Kullberg BJ, Oude Lashof AM (2002) Epidemiology of opportunistic invasive mycoses. *Eur J Med Res* 7: 183–191.
8. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, et al. (2003) Attributable mortality of nosocomial candidemia, revisited. *Clin Infect Dis* 37: 1172–1177.
9. d'Enfert C, Goyard S, Rodriguez-Arnaveilhe S, Frangeul L, Jones L, et al. (2005) CandidaDB: a genome database for *Candida albicans* pathogenomics. *Nucleic Acids Res* 33: D353–357.
10. Bailey DA, Feldmann PJ, Bovey M, Gow NA, Brown AJ (1996) The *Candida albicans* HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. *J Bacteriol* 178: 5353–5360.
11. Kumamoto CA, Vines MD (2005) Contributions of hyphae and hypha-co-regulated genes to *Candida albicans* virulence. *Cell Microbiol* 7: 1546–1554.
12. Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, et al. (2010) *Candida albicans* Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. *J Infect Dis* 201: 1718–1728.
13. Nobile CJ, Andes DR, Nett JE, Smith EJ, Yue F, et al. (2006) Critical role of Bcr1-dependent adhesins in *C. albicans* biofilm formation *in vitro* and *in vivo*. *PLoS Pathog* 2: e63.
14. Dockrell DH, Poland GA, Steckelberg JM, Wollan PC, Strickland SR, et al. (1999) Immunogenicity of three *Haemophilus influenzae* type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. *Vaccine* 17: 2779–2785.
15. Chokephaibulkit K, Phongsamart W, Vanprapar N, Chotpitayasunondh T, Chearskul S (2004) Catch-up vaccination against *Haemophilus influenzae* type b in human immunodeficiency virus-infected Thai children older than 2 years old. *Vaccine* 22: 2018–2022.



16. dos Santos Sde S, Lopes MH, Simonsen V, Caiaffa Filho HH (2004) Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. *AIDS Res Hum Retroviruses* 20: 493–496.
17. King JC, Jr., Vink PE, Farley JJ, Parks M, Smilie M, et al. (1996) Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. *Pediatr Infect Dis J* 15: 192–196.
18. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, et al. (2009) Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. *PLoS One* 4: e5392.
19. Lin L, Ibrahim AS, Xu X, Farber JM, Avenesian V, et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against *Staphylococcus aureus* and *Candida albicans* infection in mice. *PLoS Pathog* 5: e1000703.
20. Xin H, Dziadek S, Bundle DR, Cutler JE (2008) Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. *Proc Natl Acad Sci U S A* 105: 13526–13531.
21. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, et al. (2003) Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. *Antimicrob Agents Chemother* 47: 2208–2216.
22. Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, et al. (2010) A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel *in vivo* imaging technique. *Vaccine* 28: 1717–1725.
23. Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, et al. (2007) Als3 Is a *Candida albicans* Invasin That Binds to Cadherins and Induces Endocytosis by Host Cells. *PLoS Biol* 5: e64.
24. Spellberg B, Ibrahim AS, Lin L, Avenesian V, Fu Y, et al. (2008) An antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. *J Infect Dis* 197: 967–971.
25. Spellberg BJ, Collins M, French SW, Edwards JE, Jr., Fu Y, et al. (2005) A phagocytic cell line markedly improves survival of infected neutropenic mice. *J Leukoc Biol* 78: 338–344.
26. Spellberg BJ, Ibrahim AS, Avenesian V, Fu Y, Myers C, et al. (2006) Efficacy of the anti-*Candida* rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. *J Infect Dis* 194: 256–260.
27. Ibrahim AS, Spellberg BJ, Avenesian V, Fu Y, Filler SG, et al. (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. *Infect Immun* 73: 999–1005.
28. Spellberg BJ, Ibrahim AS, Avenesian V, Filler SG, Myers CL, et al. (2005) The anti-*Candida albicans* vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. *Infect Immun* 73: 6191–6193.
29. Fu Y, Luo G, Spellberg BJ, Edwards JE, Jr., Ibrahim AS (2008) Gene overexpression/suppression analysis of candidate virulence factors of *Candida albicans*. *Eukaryot Cell* 7: 483–492.
30. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE, Jr., et al. (2004) Novel inhalational murine model of invasive pulmonary aspergillosis. *Antimicrob Agents Chemother* 48: 1908–1911.
31. Ibrahim AS, Spellberg BJ, Avenesian V, Fu Y, Edwards JE, Jr. (2006) The anti-*Candida* rAls1p-N vaccine is broadly active against disseminated candidiasis. *Infect Immun* 74: 3039–3041.
32. Davis D, Edwards JE, Jr., Mitchell AP, Ibrahim AS (2000) *Candida albicans* RIM101 pH response pathway is required for host-pathogen interactions. *Infect Immun* 68: 5953–5959.